The abstract is read at the publisher; the summary is JClub's.
Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence improved median progression-free survival to 16·8 months versus 9·2 months with aromatase inhibitor plus CDK4/6 inhibitor in SERENA-6.
- Why it matters: The study addresses whether prospective ctDNA monitoring can detect acquired ESR1 resistance before radiological progression and enable an earlier endocrine switch to sustain benefit in hormone receptor–positive, HER2-negative advanced breast cancer.
- What they did: In a double-blind, placebo-controlled, randomised phase 3 trial, women and men received ESR1 ctDNA testing every 2–3 months using Guardant360 CDx, then were randomized 1:1 to switch to camizestrant 75 mg daily or continue aromatase inhibitor plus the same CDK4/6 inhibitor.
- The result: With median follow-up of 23·5 months, second progression-free survival was 25·7 months versus 19·1 months (HR 0·63, p=0·0037), supporting that this switching strategy extends first-line treatment benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.